Why we need orthogonal HCP analysis for mAbs?
- when we already have a pure mAb and a good ELISA …
Is the “needle in the haystack” ruining your mAb product?
Determining the HCP amount to a sparse sum using ELISA does not rule out that the product may contain ‘problematic’ HCPs – that may degrade the product or alter the function.
Watch this webinar to learn why you need an orthogonal method to ELISA to investigate your mAb for potentially problematic HCPs – down to and below 1ppm.